Maximize Your Impact At Immuno-Oncology Summit 2025
Immuno-Oncology Summit 2025 is a high-value forum bringing together global leaders in cancer immunotherapy to shape the next wave of scientific advances and commercial partnerships. Held August 11 at the Hilton Philadelphia at Penn’s Landing, this event convenes biotech executives, clinical developers, translational researchers, and oncology decision-makers focused on checkpoint inhibitors, T-cell therapies, combination treatments, and biomarker strategies.
Attendees are actively reviewing technology platforms, CRO capabilities, licensing relationships, and emerging product pipelines. With significant participation from senior R&D and business development leaders, the Summit offers direct access to budget holders and deal teams influencing oncology investment and collaboration strategies. The enriched attendee list lets your team filter by therapeutic focus, trial stage, and company type to connect with the right stakeholders at the right moment.
How Sales, Marketing And Revops Teams Can Use This Attendee List
For teams selling into life sciences and biotech, the Immuno-Oncology Summit 2025 attendee list provides a detailed view of stakeholders involved in oncology innovation and translational science procurement. Use attendee data to categorize contacts by research focus, clinical role, or drug development stage, then align your messaging with pipeline priorities or partnership frameworks.
Identify early-stage buyers by analyzing attendee titles such as Head of Translational Medicine, VP of Clinical Development, or Director of Business Development. Schedule pre-event meetings by leveraging verified contact details and LinkedIn profiles, increasing your booked meeting rate with scientific and commercial leads. Post-event, use the enriched conference attendee list to follow up with conversations framed around the attendee’s therapeutic area and clinical pipeline goals. This is how to get more meetings with biotech stakeholders who are actively sourcing external solutions and services in immuno-oncology.
Timing Is Everything
The Immuno-Oncology Summit 2025 takes place on August 11, 2025. With just a few months remaining, outreach timing is critical to secure high-value conversations and align sales efforts with decision-making cycles in Q3 oncology planning.
Vendelux enables teams to begin outreach early by identifying relevant contacts across trial sponsors, biotech platforms, and translational research groups. Sync your sales and marketing calendar with the enriched attendee list now to build meaningful conversations well before onsite networking begins in Philadelphia.
What’s Included In The Immuno-Oncology Summit 2025 Attendee List?
Vendelux provides visibility into executive-level attendees through a combination of organizer data and machine learning predictions. Teams can upload target account lists to identify overlap and refine their outreach strategy.
The enriched attendee list includes first and last name, job title, company name, company website, location (city, state, and country), LinkedIn profile, verified email address, and phone numbers where available. This level of detail supports contact segmentation, timely outreach, and post-event engagement tailored to the scientific and commercial goals of each attendee.
Where Is Immuno-Oncology Summit 2025?
The event will be held at Hilton Philadelphia at Penn’s Landing in Philadelphia, Pennsylvania, United States.
When Is Immuno-Oncology Summit 2025?
Immuno-Oncology Summit 2025 is scheduled for August 11, 2025.
What Type Of Event Is Immuno-Oncology Summit 2025?
This is a specialized conference focused on scientific and clinical advancements in cancer immunotherapy. The event features focused keynotes, technical panels, case study presentations, and structured networking for biotech executives, clinical researchers, regulatory leads, and business development professionals.
How Many People Attend Immuno-Oncology Summit 2025?
The event expects more than 600 attendees representing biotech, pharma, academic research, and clinical trial organizations from over 20 countries. The audience includes a strong representation of senior leaders, including heads of R&D, clinical operations leads, and corporate strategy executives.
